Key clinical point: HCC patients treated with lenvatinib showed longer progression-free survival compared to those treated with sorafenib (hazard ratio 0.40, P = 0.004).
Major finding: In a propensity score matching analysis, progression-free survival was greater in HCC patients treated with lenvatinib compared to those treated with sorafenib (5.2 months vs 3.3 months, respectively); overall survival was similar between the (13.3 months vs 11.8 months, respectively).
Study details: The data come from a retrospective study of 210 adults with unresectable HCC who underwent lenvatinib or sorafenib treatment between January 2018 and August 2020.
Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.
Source: Kuo Y-H et al. Front Oncol. 2021 Oct 25. doi: 10.3389/fonc.2021.737767.